Opthea Limited

OTCPK:OPTE.Y Stock Report

Market Cap: US$553.0m

Opthea Management

Management criteria checks 1/4

Opthea's CEO is Jeremy Levin, appointed in Sep 2025, has a tenure of less than a year. directly owns 0.005% of the company’s shares, worth $25.44K. The average tenure of the management team and the board of directors is 0.3 years and 1.5 years respectively.

Key information

Jeremy Levin

Chief executive officer

US$533.6k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.005%
Management average tenureless than a year
Board average tenure1.5yrs

Recent management updates

Recent updates

Opthea: Small Australian Company Aiming To Upend The Wet AMD Market

Jan 30

Opthea Limited: Major Catalyst In Early 2025 For Complementary Eye Disease Candidate

Nov 07

Opthea GAAP EPS of -$0.26 misses by $0.03

Aug 30

Opthea receives $170M in non-dilutive financing for OPT-302 in wet AMD

Aug 15

CEO

Jeremy Levin (72 yo)

less than a year
Tenure
US$533,568
Compensation

Dr. Jeremy Max Levin, M.D., Ph D., BA Zoology, DPhil, MB BChir, is Executive Chairman of Ovid Therapeutics Inc. from January 1, 2026 and has been its Chairman since April 2014 and serves as its Director si...


Leadership Team

NamePositionTenureCompensationOwnership
Jeremy Levin
CEO & Chairpersonless than a yearUS$533.57k0.0046%
$ 25.4k
Hamish George
CFO & Joint Company Secretaryless than a yearno datano data
Stephanie Vipond
Joint Company Secretaryless than a yearno datano data
0.3yrs
Average Tenure

Experienced Management: OPTE.Y's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jeremy Levin
CEO & Chairperson5.3yrsUS$533.57k0.0046%
$ 25.4k
Lawrence Gozlan
Independent Non-Executive Director5.5yrsUS$810.04k0.14%
$ 759.0k
Katherine Connell
Independent Non-Executive Director1.2yrsUS$87.25kno data
Patricio Schlottmann
Member of Medical Advisory Board1.5yrsno datano data
Tien Wong
Member of Medical Advisory Board1.5yrsno datano data
1.5yrs
Average Tenure
58yo
Average Age

Experienced Board: OPTE.Y's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/20 14:18
End of Day Share Price 2026/01/16 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Opthea Limited is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elyse ShapiroCanaccord Genuity
John SavinEdison Investment Research
Chris CooperGoldman Sachs